Abstracts tagged "axial spondyloarthritis"

Abstract Number: 622 • 2019 ACR/ARP Annual Meeting
Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Jean Liew¹, John Reveille ², Henna Sawhney ³, Maria Castillo ³, Benjamin Naovarat ⁴, Susan Heckbert ¹ and Lianne Gensler ⁵, ¹University of Washington, Seattle, WA, ²University of Texas McGovern Medical School, Houston, ³University of California in San Francisco, San Francisco, CA, ⁴University of Texas-McGovern Medical School, Houston, TX, ⁵University San Francisco California, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in axial spondyloarthritis (axSpA). The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high intensity statin…
Abstract Number: 1084 • 2019 ACR/ARP Annual Meeting
Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Stylianos Georgiadis ², Ulf Lindström ³, Anne Gitte Loft ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Nurullah Akkoç ⁷, Florenzo Iannone ⁸, Eirik Kristianslund ⁹, Anna Mari Hokkanen ¹⁰, Maria José Santos ¹¹, Catalin Codreanu ¹², Carlos Sánchez-Piedra ¹³, Matija Tomsic ¹⁴, Bjorn Gudbjornsson ¹⁵, Irene van der Horst-Bruinsma ¹⁶, Johan Askling ¹⁷, Michael J. Nissen ¹⁸, Karel Pavelka ⁶, Ozgül Gunduz ⁷, Fabiola Atzeni ¹⁹, Joe Sexton ²⁰, Dan Nordström ²¹, Helena Santos ²², Ruxandra IONESCU ²³, Manuel Pombo-Suarez ²⁴, Ziga Rotar ²⁵, Arni Jon Geirsson ²⁶, Marleen van de Sande ¹⁶, Gary Macfarlane ²⁷, Brigitte Michelsen ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³University of Gothenburg, Gothenburg, Sweden, ⁴Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ¹⁵Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁷Karolinska Institutet, Stockholm, Sweden, ¹⁸University Hospital Geneva, Geneva, Switzerland, ¹⁹Department of Medicine, Messina, Italy, ²⁰Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²¹Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ²²Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ²⁵UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ²⁶Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have vastly improved prognosis in patients with axial spondyloarthritis (axSpA). However, many patients treated with TNFi still fail to…
Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Gareth Jones¹, Linda Dean ¹, Ejaz Pathan ² and Gary Macfarlane ¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Toronto Western Hospital, Toronto, Canada
Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens¹, Philipp Sewerin ², Eugenio de Miguel ³, Yusuf Patel ⁴, Anastas Batalov ⁵, Eva Dokoupilova ⁶, Christine Kleinmond ⁷, Effie Pournara ⁸, Ankita Shekhawat ⁹, Claudia Jentzsch ¹⁰, Annette Wiedon ¹⁰ and Xenofon Baraliakos ¹¹, ¹CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…
Abstract Number: 557 • 2019 ACR/ARP Annual Meeting
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey
Theresa Hunter¹, David Sandoval ², Nicola Booth ³, Elizabeth Holdsworth ⁴ and Atul Deodhar ⁵, ¹Eli Lilly and Company, Indianapolis, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Manchester, England, United Kingdom, ⁵Oregon Health & Science University, Portland, OR
Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
Abstract Number: 594 • 2019 ACR/ARP Annual Meeting
Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
Walter P. Maksymowych¹, Raj Carmona ², Jonathan Chan ³, James Yeung ⁴, Sibel Zehra Aydin ⁵, Liam Martin ⁶, Ariel Masetto ⁷, Dianne Mosher ⁸, Olga Ziouzina ⁶, Stephanie Keeling ⁹, Sherry Rohekar ¹⁰, Rana Dadashova ¹¹, Joel Paschke ¹¹, Amanda Carapellucci ¹¹ and Robert Lambert ¹², ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²McMaster University, Hamilton, Canada, ³Artus Health Clinic, Vancouver, BC, Canada, ⁴Yeung Rheumatology, Vancouver, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Western University, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, Canada, ¹²University of Alberta, Edmonton, Canada
Background/Purpose: xThe ASAS classification criteria for axial spondyloarthritis (axSpA) have overall sensitivity/specificity of 82.9%/84.4% but component imaging and clinical arms differ in performance (66.2%/97.3% and…
Abstract Number: 624 • 2019 ACR/ARP Annual Meeting
Axial Spondyloarthritis: Knowledge, Screening and Referral Practices Amongst Primary Care Providers
Laura Passalent¹, Christopher Hawke ², Jeff Bloom ², Andrew Bidos ³, Soever Leslie ², Y. Raja Rampersaud ¹, Nigil Haroon ⁴ and Robert Inman ⁵, ¹Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, Canada, ³University Health Network, Toronto, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Early recognition is crucial in improving outcomes in patients with axial spondyloarthritis (axSpA). Despite this, there exists long delay between symptom onset and rheumatology…
Abstract Number: 1163 • 2019 ACR/ARP Annual Meeting
Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP
Manouk de Hooge¹, Ann-Sophie De Craemer ¹, Thomas Renson ¹, Philippe Carron ¹, Liselotte Deroo ¹, Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium
Background/Purpose: HLA-B27 and sacroiliitis on MRI form the basis of the Assessment of SpondyloArthritis international Society (ASAS) axial spondyloarthritis (axSpA) classification criteria. In addition, while…
Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Sergio Schwartzman¹, Atul Deodhar ², Andris Kronbergs ³, Silvia Santisteban ³, Sandra Garces ³, David Sandoval ³, Jeffrey Lisse ³, Fangyi Zhao ³, Denis Poddubnyy ⁴ and James Rosenbaum ⁵, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Oregon Health & Science University, Portland, OR, ³Eli Lilly and Company, Indianapolis, IN, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde¹, In-Ho Song ², Aileen Pangan ³, Atul Deodhar ⁴, Filip Van den Bosch ⁵, Walter P. Maksymowych ⁶, Tae-Hwan Kim ⁷, Mitsumasa Kishimoto ⁸, Andrea Everding ⁹, Yunxia Sui ¹⁰, Xin Wang ¹⁰, Alvina D. Chu ¹⁰ and Joachim Sieper ¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Oregon Health & Science University, Portland, OR, ⁵Ghent University Hospital, Ghent, Belgium, ⁶University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁹HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ¹⁰AbbVie Inc., Chicago, ¹¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
Abstract Number: 559 • 2019 ACR/ARP Annual Meeting
Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis
Manouk de Hooge¹, Floris van Gaalen ², Marleen van de Sande ³, Roberta Ramonda ⁴, Karen Fagerli ⁵, Lennart Jacobsson ⁶, Désirée van der Heijde ², Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University of Padova, Padova, Italy, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of Göteborg, Göteborg, Sweden
Background/Purpose: A recent study in German chronic back pain (CBP) patients (pts) with a suspicion of axial spondyloarthritis (axSpA) report on the performance of, among…
Abstract Number: 595 • 2019 ACR/ARP Annual Meeting
What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study
Walter P. Maksymowych¹, Susanne Juhl Pedersen ², Ulrich Weber ³, Pedro Machado ⁴, Xenofon Baraliakos ⁵, Joachim Sieper ⁶, Stephanie Wichuk ⁷, Denis Poddubnyy ⁸, Martin Rudwaleit ⁹, Désirée van der Heijde ¹⁰, Robert B.M. Landewé ¹¹, Joel Paschke ¹², Mikkel Østergaard ¹³ and Robert Lambert ⁷, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ³Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ⁴University College London, London, United Kingdom, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁶Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁷University of Alberta, Edmonton, Canada, ⁸Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁹Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Amsterdam University Medical Center, Amsterdam, Netherlands, ¹²CARE Arthritis, Edmonton, Canada, ¹³Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Active MRI lesions typical of axSpA were reported in 61.6% and 2.2% of axSpA and not-axSpA patients, respectively, from the ASAS classification cohort (ASAS-CC)1.…
Abstract Number: 626 • 2019 ACR/ARP Annual Meeting
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Marco Garrido-Cumbrera¹, Jordi Gratacós ², Eduardo Collantes ³, Pedro Zarco ⁴, Carlos Sastre ⁵, Sergio Sanz-Gómez ⁶ and Victoria Navarro-Compán ⁷, ¹Health & Territory Research, Universidad de Sevilla, Seville, Spain, Sevilla, ²Hospital Universitari Parc Taulí, Sabadell, I3PT, UAB, Spain, Sabadell, Spain, ³Reina Sofia University Hospital, Spain. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain, Cordova, Spain, ⁴Hospital Universitario Fundación Alcorcón, Madrid, Spain, Madrid, Spain, ⁵Novartis Spain, Barcelona, Spain, Barcelona, Spain, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, ⁷University Hospital La Paz, IdiPaz, Madrid, Spain
Background/Purpose: Most research studies support the fact that both, radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA), share similar clinical characteristics and equivalent burden of…
Abstract Number: 1175 • 2019 ACR/ARP Annual Meeting
Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA
Xenofon Baraliakos¹, Philipp Sewerin ², Eugenio de Miguel ³, Christine Kleinmond ⁴, Ankita Shekhawat ⁵, Annette Wiedon ⁶ and Frank Behrens ⁷, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁶Novartis Pharma GmbH, Nürnberg, Germany, ⁷CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
Background/Purpose: Enthesitis is a hallmark feature of Spondyloarthritis (SpA), and frequently localizes at the Achilles tendon1. Enthesitis is predominantly measured with clinical scores like Leeds…
Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].